Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world
Anselm K. Gitt,
Dominik Lautsch,
Jean Ferrieres,
John Kastelein,
Heinz Drexel,
Martin Horack,
Philippe Brudi,
Brecht Vanneste,
Peter Bramlage,
Francois Chazelle,
Vasilisa Sazonov,
Baishali Ambegaonkar
Affiliations
Anselm K. Gitt
Klinikum der Stadt Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany
Dominik Lautsch
Merck & Co., Inc., Kenilworth, NJ, USA
Jean Ferrieres
Toulouse University School of Medicine, Toulouse, France
John Kastelein
Department of Vascular Medicine, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
Heinz Drexel
Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
Martin Horack
Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany
Philippe Brudi
Merck & Co., Inc., Kenilworth, NJ, USA
Brecht Vanneste
Merck & Co., Inc., Kenilworth, NJ, USA
Peter Bramlage
Institute for Pharmacology and Preventive Medicine, Mahlow, Germany
Data presented here refer to 57,885 patients on lipid-lowering statin therapy from the Dyslipidaemia International Study (DYSIS) registry. Subjects were divided into 3 discrete subsets: those at very high-risk, high-risk, and non-high-risk for cardiovascular events, with assigned low density lipoprotein cholesterol (LDL-C) targets of 70 mg/dl, 100 mg/dl and 115 mg/dl, respectively. Overall, the highest proportion of patients meeting their LDL-C target was seen in the UAE and Kuwait (49.5%), while the lowest was seen in Germany (14.3%). The smallest median distance to target was documented in Canada (18.8 mg/dl), and the largest in the Baltics (42.1 mg/dl). Interpretation and discussion of this data can be found in the manuscript entitled “Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients” (Gitt et al., 2016) [1].
